Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974868 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT02974868 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 142 participants.
The verdict
NCT02974868, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.
Interventions
- DRUG Placebo
- DRUG PF-06651600
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2019-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02974868
The ClinicalTrials.gov registry entry for NCT02974868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02974868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02974868 about?
NCT02974868 is a clinical study titled "Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata". This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Sing...
What is the current status of trial NCT02974868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2016-12-15. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT02974868?
The interventions under investigation include: Placebo (DRUG), PF-06651600 (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT02974868?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.